ABCG2 and non-small cell lung carcinoma: The link of ABCB1 to NSCLC chemoresistance remained inconclusive [14–16], although drugs like erlotinib, irinotecan etc. that are widely used in combination therapy of NSCLC are ABCB1 and ABCG2 substrates [17, 18].